Medtide (FRA:FQ2) Other Stockholders Equity: €156.37 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FQ2 Medtide Inc FRA:FQ2
31 GF Score
Price €2.18
View Full Analysis

What is Medtide Other Stockholders Equity?

Medtide FRA:FQ2 -6.03% 31 Other Stockholders Equity is €156.37 Mil as of Dec. 2025. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100.

Medtide's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €156.37 Mil.

Medtide's quarterly Other Stockholders Equity increased from Dec. 2024 (€33.81 Mil) to Jun. 2025 (€160.24 Mil) but then declined from Jun. 2025 (€160.24 Mil) to Dec. 2025 (€156.37 Mil).

Medtide's annual Other Stockholders Equity increased from Dec. 2023 (€32.37 Mil) to Dec. 2024 (€33.81 Mil) and increased from Dec. 2024 (€33.81 Mil) to Dec. 2025 (€156.37 Mil).

Medtide Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medtide's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtide Other Stockholders Equity Chart

Medtide Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
0.83 1.76 32.37 33.81 156.37

Medtide Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only 32.60 33.81 160.24 156.37 191.45
FRA:FQ2
31GF Score
Medtide Inc FRA:FQ2
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtide Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €156.37 Mil mean?
Medtide (FRA:FQ2) has a Other Stockholders Equity of €156.37 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medtide and its competitors.
Is Medtide's Other Stockholders Equity too high?
Medtide's current Other Stockholders Equity is €156.37 Mil. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's Other Stockholders Equity compare to VRTX and REGN?
Medtide's Other Stockholders Equity of €156.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medtide and its competitors. Medtide's current Other Stockholders Equity is €156.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current Other Stockholders Equity of €156.37 Mil. The current Other Stockholders Equity is €156.37 Mil. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current Other Stockholders Equity is €156.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medtide Business Description

Other Exchanges 03880:Hong Kong
Address No. 69, 12 Street, Qiantang District, Zhejiang, Hangzhou, CHN
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score

Get the complete analysis for FRA:FQ2

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.18
Price